FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898077402> ?p ?o ?g. }

• W2898077402 abstract "Citicoline can have beneficial effects both in degenerative and in vascular cognitive decline; it works through an increase in acetylcholine intrasynaptic levels and by promoting phospholipid synthesis, (chiefly phosphatidylcholine), cellular function, and neuronal repair. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for the treatment of mild to moderate Alzheimer's disease (AD). When co-administered they could have a synergistic action in patients affected with AD and mixed dementia (MD) too. The aim of the present study was to show the effectiveness of oral citicoline plus memantine in patients affected with AD and MD. This was a retrospective study between 2015 and 2017 on 120 patients consecutive patients aged 65 years old or older affected with AD or MD (mean age 81,04 ± 5.1 years old). These data are preliminary because the study is in progress and involves different centers for dementia all over Italy. 58 patients were treated with memantine (group A), 62 patients with memantine plus citicoline 1g/day given orally (group B). In both groups memantine dosage was 10-20 mg/day according to its tolerability. 22 patients of group A and 27 patients of group B were affected with MD. Cognitive functions were assessed by MMSE, daily life functions by ADL and IADL, behavioral symptoms by NPI, comorbidities by CIRS, and mood by GDS-short form. Tests were administered at baseline (T0), after 6 (T1), and 12 months (T2). The primary outcomes were the effects of combined treatment versus memantine alone on cognitive functions assessed by MMSE. The secondary outcomes were possible side effects or adverse events of combination therapy versus memantine alone, influence on daily life functions and behavioral symptoms. Patients treated with citicoline plus memantine showed a statistically significant increase in MMSE between T0 and T1 (16.6 ± 2.69 vs 17,4 ± 2.71; p = 0.000) and between T1 and T2 (17,4 ± 2.71 vs 17.7 ± 2.8; p =0.000). Since it is important to maximize the present pharmacological means in AD and MD, this study encourages the role of combined administration of memantine plus citicoline in disease management by slowing disease progression." @default.
• W2898077402 created "2018-10-26" @default.
• W2898077402 creator A5005367261 @default.
• W2898077402 creator A5013093034 @default.
• W2898077402 creator A5090988550 @default.
• W2898077402 date "2018-07-01" @default.
• W2898077402 modified "2023-10-16" @default.
• W2898077402 title "P4‐001: THE CITIMEM STUDY: CITICOLINE PLUS MEMANTINE IN AGED PATIENTS AFFECTED WITH ALZHEIMER'S DISEASE AND MIXED DEMENTIA STUDY: PRELIMINARY DATA" @default.
• W2898077402 doi "https://doi.org/10.1016/j.jalz.2018.06.2403" @default.
• W2898077402 hasPublicationYear "2018" @default.
• W2898077402 type Work @default.
• W2898077402 sameAs 2898077402 @default.
• W2898077402 citedByCount "1" @default.
• W2898077402 countsByYear W28980774022021 @default.
• W2898077402 crossrefType "journal-article" @default.
• W2898077402 hasAuthorship W2898077402A5005367261 @default.
• W2898077402 hasAuthorship W2898077402A5013093034 @default.
• W2898077402 hasAuthorship W2898077402A5090988550 @default.
• W2898077402 hasConcept C126322002 @default.
• W2898077402 hasConcept C15744967 @default.
• W2898077402 hasConcept C197934379 @default.
• W2898077402 hasConcept C2777952318 @default.
• W2898077402 hasConcept C2778375690 @default.
• W2898077402 hasConcept C2779134260 @default.
• W2898077402 hasConcept C2779483572 @default.
• W2898077402 hasConcept C2779484449 @default.
• W2898077402 hasConcept C2780496003 @default.
• W2898077402 hasConcept C2780904820 @default.
• W2898077402 hasConcept C502032728 @default.
• W2898077402 hasConcept C71924100 @default.
• W2898077402 hasConcept C98274493 @default.
• W2898077402 hasConceptScore W2898077402C126322002 @default.
• W2898077402 hasConceptScore W2898077402C15744967 @default.
• W2898077402 hasConceptScore W2898077402C197934379 @default.
• W2898077402 hasConceptScore W2898077402C2777952318 @default.
• W2898077402 hasConceptScore W2898077402C2778375690 @default.
• W2898077402 hasConceptScore W2898077402C2779134260 @default.
• W2898077402 hasConceptScore W2898077402C2779483572 @default.
• W2898077402 hasConceptScore W2898077402C2779484449 @default.
• W2898077402 hasConceptScore W2898077402C2780496003 @default.
• W2898077402 hasConceptScore W2898077402C2780904820 @default.
• W2898077402 hasConceptScore W2898077402C502032728 @default.
• W2898077402 hasConceptScore W2898077402C71924100 @default.
• W2898077402 hasConceptScore W2898077402C98274493 @default.
• W2898077402 hasIssue "7S_Part_27" @default.
• W2898077402 hasLocation W28980774021 @default.
• W2898077402 hasOpenAccess W2898077402 @default.
• W2898077402 hasPrimaryLocation W28980774021 @default.
• W2898077402 hasRelatedWork W1979069737 @default.
• W2898077402 hasRelatedWork W2205837457 @default.
• W2898077402 hasRelatedWork W2415396619 @default.
• W2898077402 hasRelatedWork W3022305077 @default.
• W2898077402 hasRelatedWork W3109303516 @default.
• W2898077402 hasRelatedWork W3209969788 @default.
• W2898077402 hasRelatedWork W4206258100 @default.
• W2898077402 hasRelatedWork W4285307074 @default.
• W2898077402 hasRelatedWork W4312720209 @default.
• W2898077402 hasRelatedWork W65830589 @default.
• W2898077402 hasVolume "14" @default.
• W2898077402 isParatext "false" @default.
• W2898077402 isRetracted "false" @default.
• W2898077402 magId "2898077402" @default.
• W2898077402 workType "article" @default.